Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - Astria Therapeutics, Inc. | a2225036zs-1a.htm |
| EX-3.5 - EX-3.5 - Astria Therapeutics, Inc. | a2225036zex-3_5.htm |
| EX-5.1 - EX-5.1 - Astria Therapeutics, Inc. | a2225036zex-5_1.htm |
| EX-1.1 - EX-1.1 - Astria Therapeutics, Inc. | a2225036zex-1_1.htm |
| EX-4.1 - EX-4.1 - Astria Therapeutics, Inc. | a2225036zex-4_1.htm |
| EX-10.1 - EX-10.1 - Astria Therapeutics, Inc. | a2225036zex-10_1.htm |
| EX-10.7 - EX-10.7 - Astria Therapeutics, Inc. | a2225036zex-10_7.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 5, 2015, except for Note 15, as to which the date is June 11, 2015, in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-204144) and related Prospectus of Catabasis Pharmaceuticals, Inc. dated June 11, 2015.
| /s/ Ernst & Young LLP | ||
Boston, Massachusetts June 11, 2015 |
Consent of Independent Registered Public Accounting Firm